Sarepta Therapeutics Restructures $700 Million in Convertible Debt, Extending Maturities and Strengthening Financial Flexibility Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine focused on rare diseases, has announced a significant refinancing transaction designed to strengthen its capital…
Scipher Medicine Launches ClinicalTrialRank.com: AI-Powered Platform to Predict Clinical Trial Failure and Transform Drug Development Strategy Scipher Medicine, a pioneering company in precision immunology and network medicine, has officially announced the public launch of ClinicalTrialRank.com, a first-of-its-kind artificial intelligence (AI)…
MedImpact Unveils Affordable Access to Unbranded Ustekinumab-aekn Biosimilar, Reshaping Specialty Pharmacy Market MedImpact Holdings Inc., the nation’s largest independent pharmacy benefit and healthcare solutions provider, announced a major step toward addressing escalating specialty drug costs with the launch of access…
Ifinatamab Deruxtecan Receives Breakthrough Therapy Designation from FDA for Pretreated Extensive-Stage Small Cell Lung Cancer The oncology research landscape took a significant step forward this week with the announcement that ifinatamab deruxtecan (I-DXd), an investigational antibody-drug conjugate (ADC), has been…
Grove Biopharma to Showcase Breakthrough Bionic Biologics™ at ACS Fall 2025 Symposium on Materials Biology Grove Biopharma, a private biotechnology company advancing an innovative therapeutic approach it calls Bionic Biologics™, announced that it will present updates on its research at…
Omeros Corporation Reports Second Quarter 2025 Financial Results, Advances Narsoplimab Regulatory Reviews, and Strengthens Balance Sheet Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company dedicated to developing novel therapeutics for serious diseases, today announced its financial results for the second quarter…
Scholar Rock Announces Landmark Lancet Neurology Publication of Pivotal Phase 3 SAPPHIRE Trial Results for Apitegromab in Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to advancing innovative treatments for serious neuromuscular diseases, announced today that…
Cybin Announces Major Clinical and Regulatory Milestones Alongside First Quarter Fiscal Year 2026 Financial Results Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN), a clinical-stage breakthrough neuropsychiatry company focused on transforming mental health care through the development of next-generation psychedelic-based…
Alto Neuroscience Appoints Raymond Sanchez, M.D., to Board of Directors, Strengthening Leadership as Company Advances Late-Stage Precision Psychiatry Pipeline Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company pioneering the development of novel precision medicines for neuropsychiatric disorders, today…
Innoviva Specialty Therapeutics Earns Dual Nominations for 2025 Prix Galien USA Best Pharmaceutical Product Award for ZEVTERA® and XACDURO® Innoviva Specialty Therapeutics, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced that two of its flagship infectious disease therapies…
Bayer and Kumquat Biosciences Forge Global Exclusive Agreement to Advance Next-Generation KRAS G12D Inhibitor in Precision Oncology Bayer AG, a global life sciences company with a growing presence in oncology, and Kumquat Biosciences Inc., a clinical-stage biotechnology company founded by…
PureTech Health Launches Celea Therapeutics to Transform the Treatment Landscape for Respiratory Diseases PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company committed to developing groundbreaking therapies for patients with devastating conditions, has announced…